Research programme: antibody therapeutics - Adimab/Novartis
Latest Information Update: 01 Sep 2011
At a glance
- Originator Adimab
- Developer Adimab; Novartis
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified
Most Recent Events
- 30 Aug 2011 Early research is ongoing in USA
- 12 Jul 2010 Early research in Undefined indication in USA (Parenteral)